Clinical study of evaluated the changes of activated microglia in patients of major depressive disorder and bipolar disorder: A PET study

Clinical study of evaluated the changes of activated microglia in patients of major depressive disorder and bipolar disorder: A PET study - Evaluation for activated microglia using PET in patients of major depressive disorder and bipolar disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026914

Enrollment

120

Registered

2017-04-10

Start date

2018-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder bipolar disorder

Interventions

PET:11C-DPA713(activated microglia) and 11C-DASB(serotonin transporter) 5MBq/kg i.v

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Health control -Without past or current history psychiatric illness Illnesses groups -Diagnosed as major depressive disorder and bipolar disorder on DSM-5

Exclusion criteria

Exclusion criteria: -With current history of psychiatric disorder in healthy control -critical state such as suicide attempt -With past or current history of neurological illness (including normal variant such as cave of septum pellucidum detected by MRI) -With past or current history of serious medical illness and/or brain organic diseases -taking medicines such as antiallergic, anticholinergic, antiinflammatory and immunosuppressive agents -History of alcoholics or substance abuse or addiction -In pregnancy or lactation -smoking or having smoking history

Design outcomes

Primary

Measure	Time frame
the binding potential of 11C-DPA713 and 11C-DASB in superior and anterior frontal gyrus, orbitofrontal cortex, anterior cingulate gyrus, striatum and hippocampus.	—

Secondary

Measure	Time frame
MRI: T1WI, MRS-MEGAPRESS, rs-fMRI, DTI Cytokine: FGF-2, Eotaxin, G-CSF, GM-CSF, IFN-r, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1a, MIP-1b, PDGF-BB, RANTES, TNF-a, VEGF, TGF-b1, TGF-b2, TGF-b3 Tryptophan metabolites: DL-Tryptophan, L-5-hydroxy-tryptophan, Serotonin, L-Kynurenine, 5-Hydroxytryptophol, Tryptophol, 5-hydroxyindole-3-acetic acid, indole-3-acetic acid, Anthranilate, Kynurenic Acid, Quinolinecarboxylic Acid, Indole-3-butyric acid, 3-Hydroxykynurenine, 3-hydroxyanthranilate, xanthurenic acid mature BDNF, proBDNF Psychological test: BDI-II, HDRS, YMRS, IES-R, ICG, STAI, SASS, SRRS, CGI-S, WAIS-III, JART Genetic examination: genetic polymorphism analysis and DNA methylation analysis of 5-HTT, GR, BDNF. Global DNA methylation analysis and expression analysis.	—

Measure

Time frame

MRI: T1WI, MRS-MEGAPRESS, rs-fMRI, DTI Cytokine: FGF-2, Eotaxin, G-CSF, GM-CSF, IFN-r, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1a, MIP-1b, PDGF-BB, RANTES, TNF-a, VEGF, TGF-b1, TGF-b2, TGF-b3 Tryptophan metabolites: DL-Tryptophan, L-5-hydroxy-tryptophan, Serotonin, L-Kynurenine, 5-Hydroxytryptophol, Tryptophol, 5-hydroxyindole-3-acetic acid, indole-3-acetic acid, Anthranilate, Kynurenic Acid, Quinolinecarboxylic Acid, Indole-3-butyric acid, 3-Hydroxykynurenine, 3-hydroxyanthranilate, xanthurenic acid mature BDNF, proBDNF Psychological test: BDI-II, HDRS, YMRS, IES-R, ICG, STAI, SASS, SRRS, CGI-S, WAIS-III, JART Genetic examination: genetic polymorphism analysis and DNA methylation analysis of 5-HTT, GR, BDNF. Global DNA methylation analysis and expression analysis.

—

Countries

Japan

Contacts

Public ContactYosuke Kameno

Hamamatsu University school of medicine psychiatry

kameno@hama-med.ac.jp053-435-2295

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026